Overview

A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors

Status:
TERMINATED
Trial end date:
2025-05-07
Target enrollment:
Participant gender:
Summary
The goal of this study is to obtain safety, tolerability, PK, and preliminary clinical antitumor activity for XL495 as a single agent and in combination with select cytotoxic agents in participants with locally advanced or metastatic tumors for whom life-prolonging therapies do not exist or available therapies are intolerable/no longer effective.
Phase:
PHASE1
Details
Lead Sponsor:
Exelixis